sh-Polypeptide-59 for Hair Regrowth - Quick Reference Sheet
evipedia.aidev
← Back

sh-Polypeptide-59 for Hair Regrowth

Created on 08/24/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4.5 – Audit

A laboratory-made platelet growth protein. No human hair-count trials of this ingredient alone exist; the hair case is mouse and stem-cell culture. Wound-repair data are strong; hair-density benefit when used alone is theoretical. Known tumors at the site are a reason not to use it. The safety file is large for topical wounds, thin for repeated scalp injection. (Full Review)

Protocol

Two marketed patterns
Daily leave-on or in-office after microneedling
In-office typically every 4–6 weeks for 3–4 sessions, then maintenance
In-office concentration used in a trial
300 μg/mL, up to 1.0 mL
On freshly needled facial skin; scalp clinics copy that pattern without a hair-count trial
Time of day
Leave-on often at night
Clean, dry scalp; in-office product applied immediately after needling
Time to effect
Closure of chronic diabetic neuropathic ulcers
20 weeks
Diabetic neuropathic ulcer trials; not a hair-count endpoint
Recovery of treated skin after radiofrequency microneedling
30 days
Global aesthetic scores on treated facial skin, not hair density
Hair-cycle re-entry and follicle-stem-cell support
3–6 months
Typical window for hair-cycle tools; no human timeline for isolated sh-Polypeptide-59 density

Benefits

Contraindications
  • Known neoplasm at the planned application or injection site
  • Active cutaneous or scalp malignancy, including untreated keratinocyte cancers (common cancers of the outer skin cells) in the field
  • Documented hypersensitivity to recombinant PDGF-BB or to the product vehicle
  • Children under 16 years
  • Pregnancy and lactation
    •
Key Interactions
  • Other topicals on the same site (minoxidil, corticosteroids such as clobetasol, keratolytics such as salicylic acid)
  • Angiogenesis inhibitors such as bevacizumab
  • Stacked cosmetic growth-factor serums (other recombinant growth factors plus copper tripeptide-1)
  • PRP or concentrated growth factor
  • Immunosuppressants such as cyclosporine or methotrexate
  • Paraben or m-cresol sensitivity
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Malignancy risk; application-site erythema and burning; excess granulation tissue
    •
  • Speculative: Fibrosis around hair follicles
    •

Monitoring

Marker Target Why
Hair density (trichoscopy, hairs/cm²) No established target; track change from the individual's own mapped-site baseline Primary hair-regrowth endpoint
Hair shaft diameter (μm) No established target; track change from own baseline Miniaturization versus thickening
Vellus-to-terminal ratio Shift toward terminal versus that person's baseline Marks real follicle recovery rather than persistent vellus hair
Daily shed count (collected hairs) Fall versus that person's pre-treatment average Early shedding signal
Application-site skin exam Intact skin without new papules, ulcers, or suspected tumors Catches irritation and lesions

Cadence: Matched photos and trichoscopy at about 12 weeks, 24 weeks, then every 6–12 months if use continues; lesion check at each in-office visit

Qualitative Assessment

  • New hairs at the hairline or vertex on matched photographs
  • Reduced visible scalp through the part
  • Scalp comfort versus burning or tightness after application
  • No new nodules or non-healing spots in the treated field
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.